Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • From the Analyst's Couch
  • Published:

Autism spectrum disorders

Nature Reviews Drug Discovery volume 11, pages 745–746 (2012)Cite this article

Subjects

An Erratum to this article was published on 19 October 2012

This article has been updated

Current therapeutic options

Currently, there are just two pharmacotherapies approved for the management of the disorder: risperidone (Risperdal; Johnson & Johnson) and aripiprazole (Abilify; Bristol-Myers Squibb/Otsuka Pharmaceuticals). Both of these products are atypical antipsychotics indicated for the management of irritability symptoms associated with ASDs in children and adolescents (aged 5–17 years) in the United States. There are currently no treatments approved in Japan or the five major European markets.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Prevalence of autism spectrum disorders in 2011.

Change history

  • 19 October 2012

    There were some inaccuracies in the description of the compound STX–209 (arbaclofen; Seaside Therapeutics) in the text and table of the article. The compound is currently under Phase IIb clinical investigation for the treatment of the core symptoms of autism spectrum disorders, and it is formulated as an oral rapid disintegrating tablet. This information has been updated in the online version of the article.

References

  1. Datamonitor. Epidemiology: autism spectrum disorders. increasing recognition drives growth of treatable population. Code: HC00106.001 (February 2011).

Download references

Author information

Authors and Affiliations

  1. Sarah Nightingale is an analyst at Datamonitor, 119 Farringdon Road, London EC1R 3DA, UK. snightingale@datamonitor.com,

    Sarah Nightingale

Authors
  1. Sarah Nightingale
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

The author declares no competing financial interests.

Related links

Related links

FURTHER INFORMATION

Autism Speaks website — 19 March 2012 press release

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nightingale, S. Autism spectrum disorders. Nat Rev Drug Discov 11, 745–746 (2012). https://doi.org/10.1038/nrd3771

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd3771

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research